Exploring Bacterial Therapy for Cancer Treatment

Over 150 years ago, the journey of exploring the use of bacteria in cancer treatment began, with early studies showing that bacterial infections could lead to improvements in cancer patients. Today, with ongoing scientific advancements, we find ourselves on the brink of a new era of treatments that rely on the delicate balance between two types of bacteria, known as AUN.

History of Bacterial Cancer Therapy

The concept of bacterial therapy for cancer started in 1868 when German physician Busch observed that a cancer patient who contracted a bacterial infection showed signs of improvement. In 1893, Dr. William Coley developed treatments based on bacteria, paving the way for modern immunotherapies like checkpoint inhibitors and CAR-T cell treatments.

While these therapies have revolutionized cancer care, they heavily depend on the immune system. For patients whose immunity is weakened by chemotherapy or radiation, these treatments often fail to work effectively.

Introducing AUN Technology: A Perfect Balance of Complementary Bacteria

AUN technology is a new development that directly overcomes the limitations of traditional treatments. This technique involves two types of bacteria: Proteus mirabilis (A-gyo) and Rhodopseudomonas palustris (UN-gyo). These bacteria work in harmony to destroy cancer cells in both animal and human models, even when the immune system function is compromised.

AUN technology has shown strong compatibility with the human body and minimal side effects, including the suppression of cytokine release syndrome, a potentially severe immune reaction.

How AUN Works to Eliminate Tumors

The AUN alliance derives its anti-tumor strength through a series of coordinated mechanisms that include:

Precisely targeting and destroying tumor blood vessels and cancer cells. A-gyo undergoes a structural transformation (elongation) triggered by tumor-specific metabolites, enhancing its ability to kill cancer cells. Modifying the bacterial ratio within the tumor environment from an initial mix of about 3:97 (A-gyo to UN-gyo) to about 99:1, boosting its therapeutic power.

Harmony of Opposites

UN-gyo shows its effectiveness only when paired with A-gyo, acting as a regulator that reduces harmful bacterial activity while increasing precision in killing cancer. This mutual cooperation embodies the Japanese concept of “AUN,” symbolizing balance and harmony between opposites. This precise balance is what gives the treatment its exceptional results, achieving what traditional immune-based therapies could not.

Conclusion

AUN technology stands on the verge of launching new clinical trials in the next six years, heralding the opening of a new chapter in bacterial cancer therapy. This pioneering approach represents a turning point for patients with weakened immune systems, offering a long-awaited option when traditional immune therapies fail, marking the arrival of a non-immune-based cancer treatment.